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Abstract
Background: The merozoite surface protein (MSP)-1 is a target antigen of protective immunity and a malaria
vaccine candidate. The nature of this protective immune response warrants further investigation: although specific
antibody is thought to play a major role, the mechanisms of protection are still unclear. Monoclonal antibodies
(mAbs) specific for the C-terminus of MSP-1 from Plasmodium yoelii have been shown previously to provide
protection against challenge infection when administered by passive immunization to mice. Three protective mAbs
were re-examined and, in particular, the effect of combinations of antibodies on the protection provided was
studied. It was found that a combination of two antibodies can either provide additive protective effects or result
in a suppression of protection. In this report the importance of antibody subclass and epitope specificity in the
outcome of these passive immunization experiments are discussed.
Methods: The minimum protective dose (MPD) for each mAb was determined, and then combinations of
antibody at their MPD were investigated for their ability to control parasitaemia and promote survival in groups of
mice. Mice were inoculated over three days with the MPD and challenged with a blood stage infection of the
virulent P. yoelii 17 XL. The resultant parasitaemia was assessed daily on Giemsa-stained blood films. Following the
infection the presence of MSP-1 specific antibodies in the sera was monitored, and the proliferative responses of
cells in the spleen of protected mice were measured.
Results: Combining antibodies resulted in either an additive effect on protection, with reduced peak parasitaemia
and better survival, or resulted in a suppression of protection over that achieved by a single antibody alone. An
additive effect was observed when B6 and F5 that have the same isotype and similar fine specificity, were
combined. However, a combination of mAb D3, an IgG2a, with either B6 or F5 (both IgG3) suppressed protection,
an effect that may have been due to the combination of different isotypes or to the different fine specificity of the
antibodies.
Conclusions: These results suggest that a combination of protective antibodies with either the same or different
isotypes can produce either an additive or a suppressive effect in passive immunization. This phenomenon may be
important in better understanding immunity in this experimental mouse model of malaria.
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Background
Malaria control remains one of the most important
priorities for improving public health in tropical and
subtropical areas of the world. The World Health Orga-
nization estimates that half the world’s population is at
risk and there are about 250 million clinical cases in
Africa, Asia and South-America, with up to a million
deaths a year due to malaria [1]. The malaria parasite
has evolved complex strategies to adapt to its host and
evade the immune system.
Recent studies on immunity to malaria have been lar-
gely carried in the field using human material or in the
laboratory using appropriate murine models. A large
number of parasite proteins have been studied as anti-
gens, including the merozoite surface protein (MSP)-1
[2]. The merozoite is a specialized cell that invades red
blood cells, representing an essential extracellular stage
of the asexual blood cycle. Proteins on the merozoite sur-
face are, therefore, accessible to humoral immunity and
there is considerable interest in understanding how anti-
bodies binding to these proteins can either prevent ery-
throcyte invasion or target merozoites for phagocytosis
and clearance. MSP-1 is a high-molecular-weight protein
synthesized as a precursor during schizogony, which is
found on the surface of the merozoite as a complex of
fragments derived by proteolytic processing of the pre-
cursor [2,3]. There is abundant evidence to suggest that
the C-terminal region of this molecule, represented by a
42 kDa fragment on the merozoite surface (MSP142), is
the target of antibodies that are important in protective
immunity [4]. At invasion this fragment is further cleaved
into two further fragments, one of which is the C-term-
inal 19 kDa fragment (MSP-119) that is comprised of two
epidermal growth factor-like domains and remains on
the surface of the parasite through erythrocyte invasion.
In the present work, three monoclonal antibodies
(mAbs) that bind to the C-terminus of Plasmodium yoe-
lii MSP-1 were used, which all individually provide pro-
tection against a challenge infection following passive
immunization of mice [5]. The three antibodies that
have both different and similar fine specificities and iso-
types, are D3 (IgG2a), F5 (IgG3) and B6 (IgG3). B6 and
F5 both bind to the first epidermal growth factor (EGF)
domain in MSP-119 with a similar fine specificity, whilst
D3 binds to an epitope that is only found on the intact
MSP-142. The aim of this study was to investigate the
possible suppressive, synergistic or additive effects of
combining these mAbs in passive immunization experi-
ments using groups of BALB/c mice.
Methods
Monoclonal antibodies (mAbs)
Hybridomas expressing the mAbs B6 (IgG3), D3 (IgG2a)
and F5 (IgG3) were maintained and cultured as
described previously [5]. Immunoglobulins were
purified from hybridoma culture supernatants using pro-
tein G-Sepharose according to the manufacturer’s
recommendations.
Passive immunization and parasite challenge
Eight week-old female BALB/c mice bred under specific-
pathogen-free conditions were used in groups of six.
The purified mAbs dissolved in phosphate buffered sal-
ine (PBS) were administered by intraperitoneal injection
on three occasions, i.e. one day before, one day after
and on the day of challenge infection. The parasite chal-
lenge was administered by intravenous injection of five
thousand parasitized erythrocytes, at least one hour after
administration of the mAb. The parasite used for the
challenge was the lethal 17XL strain of P. yoelii; the
parasite was stored at - 80°C and passaged once in a
mouse before use in these experiments. Blood stage
parasitaemia was assessed daily on smears made from
tail blood and stained with Giemsa’s reagent.
The amount of antibody to be used in the passive
immunization experiments was determined in prelimin-
ary experiments carried out to establish the minimum
protective dose (MPD), using a range down to one fifth
of the 1.5 mg amount used previously [5]. All animal
experimentation was approved by the Ethical Review
board of USB.
Western blot assay
To detect antibodies to MSP-1 in the sera from the
immunized mice, a western blot assay was used. A
recombinant protein comprised of glutathione S-trans-
ferase fused to the two C-terminal MSP-1 epidermal
growth factor-like domains (GST-MSP-119) was
expressed in Escherichia coli and purified from the bac-
terial lysates as described previously [6]. The purified
protein was subjected to SDS-PAGE and then electro-
phoretically transferred to nitrocellulose paper (NCP,
0.2 μm pore size; Schleicher & Schuell), at 120 mA in a
transblotting chamber (Bio-Rad, Instruments), for one
hour at 4°C, using 25 mM Tris-HCl, 150 mM glycine,
20% v/v methanol, by the method of Towbin and co-
workers [7]. After transfer, the blots were blocked by
incubation with a solution of 3% w/v non-fat milk in
PBS for 30 min at room temperature, and washed three
times (3×) in PBS, containing 0.05% v/v Tween-20. Blots
were then incubated for one hour at room temperature
with a solution of primary antibody diluted 1:200 in
PBS, washed 3× and incubated in a solution of affinity
purified goat anti-mouse immunoglobulin conjugated to
horseradish peroxidase, at a 1:1,000 dilution (Sigma), for
a further one hour. The blots were washed again 3
times and antibody binding was detected by incubation
in a solution of 3 mg ml-1 4-chloro-1-napthol in
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methanol, mixed with 50 ml of 50 mM Tris-HCl pH 7.5,
and 30 μL of 30% H2O2. The colour reaction was
stopped by washing with H2O.
Cell proliferation assay
Cells were harvested from the spleens of naïve mice or
surviving mice in the group that had been passively
immunized with the combination of B6 and F5 mAbs,
and placed into culture in sterile 96-well tissue culture
plates with minimum essential medium (MEM) supple-
mented with 20 mM L-glutamine, 16.5 mM NaHCO3,
10% v/v foetal calf serum and 2% antibiotic (penicillin/
streptomycin) solution. A suspension of 2 × 105 cells
was placed in each well with 10 or 20 μg of either
recombinant MSP-119 protein or concanavalin A
(ConA) as a lymphocyte mitogen control, or buffer
alone as a negative control. After 48 hours of incubation
at 37°C and in an atmosphere of 5% v/v CO2 in air, cell
viability and proliferation was assessed spectrophotome-
trically following the addition of 20 μl of MTS reagent
([3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphe-
nyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt; MTS
(a)], CellTiter 96® AQueous, Promega). The reduction in
absorbance at 490 nm for the treated and untreated
control cultures was measured and compared.
Statistical analysis
Each experimental value is presented as the mean of six
replicates ± standard deviation. Once normality and
homogeneity criteria were satisfied, statistical analyses
were carried out by one-way ANOVA, taking a = 5%
(p < 0.05) as significant.
Results
In the first series of studies, the MPD was established
for each mAb. For each of the three mAbs a total dose
of 0.3 mg (i.e. 0.1 mg delivered on three occasions)
modulated the course of infection but was not protec-
tive. At a higher dose (0.6 mg of mAb D3; 0.9 mg of B6
and 1.2 mg of F5) a clear protective effect was seen for
each of the antibodies (data not shown). In the control
group inoculated with PBS alone a fulminating infection
resulted in high parasitaemia with no survival past day
10. In contrast passive immunization with 0.6 mg of
mAb D3 delayed the course and reduced the peak of
parasitaemia as well as improving survival (Figure 1). All
animals were alive on day 10 and 20% survived to the
end of the experiment on day 30. There was a 2-day
delay in patent parasitaemia, which then increased to
63% only by day 14 followed by clearance of parasites
by day 22. The difference in parasitaemia between
experimental and control group, for example at day 9,
was statistically significant.
Then, the consequence of passive immunization with
mixtures of the mAbs at their MPD was examined,
expecting an additive effect. The effect of immunization
with a combination of D3 and B6 mAbs is shown in
Figure 2. As can be seen from this graph, passive
Figure 1 Passive immunization with the minimal protective dose (MPD) of mAb D3. The bars represent the percentage survival and the
lines the percentage parasitaemia for the control group of animals and the group receiving mAb D3.
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immunization with a mixture of these antibodies pro-
duced a lower level of protection than that achieved
with individual mAbs alone. There was a protective
effect when the survival rate and parasitaemia were
compared to that in the control group injected with PBS
alone in which group there was nearly 90% parasitaemia
and no survival beyond day 10. However, parasite devel-
opment in the presence of this combination resulted in
both higher mortality (20% survival by day 14) and para-
sitaemia (85% on day 14) when compared with the pro-
tection given by B6 (57% parasitaemia) or D3 (63%
parasitaemia) alone. Thus the suppressive effect on
parasitaemia of the combination was less than that
achieved by the individual antibodies given separately. A
similar suppressive effect was observed in a passive
immunization experiment using a combination of the
D3 and F5 mAbs. As shown in Figure 3, the combina-
tion of D3 and F5 resulted in 70% parasitaemia at day 9
compared to 63% and 66% for D3 and F5 alone, respec-
tively. On this occasion, none of the control mice sur-
vived beyond day 5 with a 70% parasitaemia, consistent
with a higher parasite challenge inoculum.
The third possible combination of antibodies was
mAbs B6 with F5, both of which are of the IgG3 isotype.
Figure 2 Passive transfer experiment with the mAbs D3 and B6 in combination. The bars represent the percentage of survival and the
lines the percentage of parasitaemia.
Figure 3 Passive transfer experiment with the mAbs D3 and F5 in combination. The bars represent the percentage of survival and the
lines the percentage of parasitaemia.
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In this case the outcome of the passive immunization
with the combination was a clear additive effect, as
shown in Figure 4. In this experiment none of the control
group survived beyond day 7 and with a parasitaemia
greater than 70%. In contrast all the mice that received
this combination of antibodies survived to the end of the
experiment at day 30 with no detectable parasites after
day 23. Furthermore the maximum parasitaemia was
43%, considerably lower than that in the groups given
mAbs B6 and F5 separately. In these passive immuniza-
tion experiments, from day 2 there was a significantly
lower parasitaemia (p ≤ 0.05) than in the control group.
In order to confirm that the mice from the group pro-
tected by passive immunization with B6 and F5 did not
have subpatent parasites after clearance of parasitaemia,
a 200 μl blood sample was taken and inoculated intrave-
nously into a naive mouse; no parasites were detected in
these animals during the 30-day monitoring period.
To confirm the presence of antibodies to MSP-1 in
the surviving animals from the different groups, serum
samples were examined by western blotting against a
GST-MSP119 fusion protein. Antibodies were detected
in all of the serum samples from mice that had been
administered the mAbs either alone or in combination
except for the group that received a mixture of B6 and
F5 mABs (Figure 5).
To examine whether or not passive immunization and
challenge infection induced an immune response,
Figure 4 Passive transfer experiment with the mAbs B6 and F5 together in combination. The bars represent the percentage of survival
and the lines the percentage of parasitaemia.
Figure 5 Western blot analysis of the sera from the surviving animals from the passive transfer experiments (PTE). (1). Normal mouse
serum, (2). Serum from PTE of D3+B6, (3). Serum from PTE of D3+F5, (4). Serum from PTE of B6+F5, (5). Serum from PTE of D3, (6). Serum from
PTE of B6, (7). Serum from PTE of F5. The arrow indicates the location of the recombinant 46 kDa GST-MSP-119 protein.
Eslava et al. Malaria Journal 2010, 9:46
http://www.malariajournal.com/content/9/1/46
Page 5 of 8
splenic lymphocytes from the group immunized with the
combination of B6 and F5 antibodies were examined for
their ability to proliferate in the presence of recombi-
nant MSP-1, as shown in Table 1. Lymphocyte prolifera-
tion in the presence of recombinant MSP-1 protein was
similar to that in the presence of the mitogen Con A,
and much higher than the proliferative response to
MSP-119 of lymphocytes from naïve mice, indicating
that an immune response had been induced in these
protected animals.
Discussion
It is well established that immunization of mice with the
C-terminal region of MSP-1 is able to induce protective
immunity [6,8,9]. What is less clear are the protective
mechanisms responsible. There is good evidence that
antibody plays an important role in the protection
induced [5,6,10], but the whether the antibody works by
directly neutralizing merozoites and blocking erythro-
cyte invasion or primarily through Fc-mediated actions
needs further investigation.
The ability of three monoclonal antibodies specific for
the merozoite surface protein MSP-1 to provide protec-
tion against infection with the rodent malaria parasite
P. yoelii by passive immunization was investigated. In
particular we have examined the effect of combining
pairs of antibodies on their protective capacity. These
antibodies are of the G3 (B6 and F5) and G2a (D3) iso-
types. Both B6 and F5 bind to an epitope within the
first EGF-like domain of P. yoelii MSP-119, whereas D3
binds to an epitope in the longer MSP142 fragment,
which is formed from the two subdomains of MSP133
and MSP119 [5]. The epitopes binding B6 and F5 over-
lap but are not identical [5,11], but their proximity to
the epitope of D3 is unclear since the epitope for this
antibody appears to be a conformational epitope that is
formed only in the intact MSP-142. In the first step of
this study, the minimum protective dose (MPD) was
determined for each antibody as 0.6, 0.9 and 1.2 mg for
mAbs D3, B6 and F5, respectively. In the second step of
the study, the ability of combinations of two antibodies
at their MPD to provide protection by passive immuni-
zation was measured. Mixtures of D3 and B6 or D3 and
F5 antibodies were less effective than the single antibo-
dies alone, whereas a mixture of F5 and B6 was more
effective than either of these two antibodies alone.
The mechanism(s) by which these three antibodies pro-
vide protection following passive immunization is
unknown. There are several mechanisms that have been
suggested to explain the protective effect of antibodies to
merozoite surface proteins [12], and a number of possible
mechanisms have been identified for antibodies directed
against the C-terminal region of Plasmodium falciparum
MSP-1 [4]. These mechanisms may depend on the anti-
body alone, such as inhibition of proteolytic processing
of MSP-1 or merozoite agglutination, or depend on an
Fc-mediated component such as opsonisation of mero-
zoites and phagocytosis. In both types of mechanism it is
likely that the antibody avidity and concentration are
important. In the case of antibody mediated inhibition of
invasion through inhibition of MSP-1 processing the fine
specificity of antibody binding is crucial. Antibodies that
bind to the first EGF-like domain, such as B6 and F5 can
inhibit processing but the importance of this mechanism
in protection against P. yoelii has not been established. If
both B6 and F5 mAbs are providing protection through
this mechanism, it is not surprising that the protection
provided by passive immunization with a mixture of the
two is additive since this is equivalent to increasing the
concentration of the protective antibody specificity. In
fact, the mice in this group fully resolved their parasitae-
mia since a blood sample that was transferred from each
mouse into naïve recipient mice failed to cause infection.
However, it is also possible that an acquired immune
response as indicated by the lymphocyte proliferation
(Table 1) and resulting from the parasite infection may
have also contributed to this clearance.
The failure of mixtures of B6 with D3 or F5 with D3
to provide additive protection is more difficult to
explain. mAb D3 does not bind to MSP119 alone and
yet is very effective at providing protection on passive
immunization; a corresponding antibody specific for P.
falciparum MSP-1 has not been described or a mechan-
ism evaluated. The suppressive effect of the mixture on
the control of parasitaemia highlights the potential com-
plexity of antibody interactions within a polyclonal
response. It has already been established that some anti-
bodies, which do not inhibit MSP-1 processing, can be
defined as blocking antibodies in this mechanism
because they block the binding of the inhibitory anti-
body [4,13,14]. It is not known whether or not the bind-
ing of D3 to MSP-1 competes with and blocks the
binding of B6 or F5 mAbs, or vice versa. In either case
Table 1 Cell proliferation assay following recovery from
infection
Spleen cell source Stimulant Amount (μg) Absorbance
Normal MSP-119 10 0.090
Normal MSP-119 20 0.072
F5+B6 recovered Con A 10 0.302
F5+B6 recovered Con A 20 0.329
F5+B6 recovered MSP-119 10 0.338
F5+B6 recovered MSP-119 20 0.445
Normal spleen corresponds to cells from naïve mice as negative control and
cells stimulated with Con A are a positive control of proliferation/viability,
detected in the MTS assay. A blank value of 0.147, obtained with normal
spleen cells without stimulation with MSP-119 or ConA, was subtracted from
each absorbance value. Each absorbance value represents the mean from
three independent experiments.
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the consequence may be a reduction in the protective
capacity of the mixture of antibodies, as seen in the
results presented here.
An alternative explanation may reflect the importance
of Fc-mediated mechanisms in the protection mediated
by passive immunization with antibodies to MSP-1,
which may depend on the isotype of the mAb. It has
already been established that Fc-mediated effects are
important in immunity dependent on antibodies binding
to MSP-1 [15,16], although some studies have shown
that this mechanism is not essential [17,18]. One possi-
ble explanation for the results is that the IgG3 isotype
has a greater capacity to fix complement than IgG2a
[19]. Although the FcgRI receptor of macrophages has a
high affinity for IGg2a, it binds IgG3 with fivefold higher
affinity [20,21]. In competition studies, it has been
demonstrated that IgG3 can inhibit IgG2a binding to
FcgRI receptor [21]. Earlier work with a different IgG3
specific for MSP-1 also showed that it was effective in
passive protection [10]. This interpretation would sug-
gest that IgG3 is the best immunoglobulin sub-class for
use in passive immunization to eliminate the parasite
from the blood.
Smith and Taylor-Robison [22] measured the level of
different immunoglobulin isotypes induced during infec-
tions of mice with virulent and avirulent lines of Plas-
modium chabaudi and Plasmodium yoelii. A non-lethal
infection was characterized by early upregulation of
IgG2a and late upregulation of IgG1, whereas in a lethal
infection a slow and reduced IgG2a correlated with
rapid fatal outcome before G1 synthesis. Unfortunately
these authors did not evaluate the IgG3 isotype.
The proliferation of spleen cells following stimulation
with MSP-119 was observed for the group of mice that
was protected by passive transfer of B6 and F5 antibo-
dies, and which was similar in magnitude to that
induced by the mitogen ConA and was not replicated
when the spleen cells came from normal BALB/c mice.
Since the passive immunization did not result in sterile
immunity it is likely that the infection induced an
acquired immune response in these animals. This
immune response may have contributed to the observed
control of infection, in addition to that resulting from
the presence of the B6 and F5 antibodies. In fact, anti-
bodies to MSP-119 were not detected by western blot-
ting in the serum samples from the mice in this group
taken after the infection had been cleared, suggesting
that all of the passively transferred antibodies had been
consumed and other mechanisms might have provided
the final clearance of parasites.
Conclusions
These studies highlight the fact that monoclonal antibo-
dies binding to the C-terminus of MSP-1 can provide
protection by passive immunization. However, the out-
come of using combinations of protective antibodies,
which have both the same or different isotypes and dif-
ferent epitopes, can produce additive or suppressive
effects in passive immunization experiments. These
observations highlight the complexity of the interaction
of antibodies with the surface of the merozoite and may
be important in understanding immunity in this experi-
mental mouse model of malaria. Whilst passive immuni-
zation with single antibodies may have potential clinical
therapeutic application [23], combinations of antibodies
would need to be evaluated very carefully. The results
are important in the context of malaria vaccine design
since stimulation of the appropriate antibody response
either by antigen engineering or by use of appropriate
adjuvant may be a critical component in vaccine
development.
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